![](/img/cover-not-exists.png)
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Oza, Amit M., Tinker, Anna V., Oaknin, Ana, Shapira-Frommer, Ronnie, McNeish, Iain A., Swisher, Elizabeth M., Ray-Coquard, Isabelle, Bell-McGuinn, Katherine, Coleman, Robert L., O'Malley, David M., LeLanguage:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2017.08.022
Date:
September, 2017
File:
PDF, 1.69 MB
english, 2017